BlackRock
NPCE icon

BlackRock’s Neuropace NPCE Stock Holding History

BlackRock’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4M Buy
2,477,603
+131,270
+6% +$2.11M ﹤0.01% 2826
2026
Q1 		$30.9M Sell
2,346,333
-37,584
-2% -$564K ﹤0.01% 2806
2025
Q4 		$36.8M Sell
2,383,917
-32,736
-1% -$438K ﹤0.01% 2726
2025
Q3 		$24.9M Buy
2,416,653
+97,487
+4% +$919K ﹤0.01% 2950
2025
Q2 		$25.8M Buy
2,319,166
+1,463,858
+171% +$18.3M ﹤0.01% 2856
2025
Q1 		$10.5M Buy
855,308
+109,180
+15% +$1.37M ﹤0.01% 3291
2024
Q4 		$8.35M Buy
746,128
+41,379
+6% +$360K ﹤0.01% 3519
2024
Q3 		$4.91M Buy
704,749
+33,874
+5% +$248K ﹤0.01% 3704
2024
Q2 		$5.07M Buy
670,875
+596,721
+805% +$6.02M ﹤0.01% 3680
2024
Q1 		$979K Sell
74,154
-12,348
-14% -$176K ﹤0.01% 4201
2023
Q4 		$892K Buy
86,502
+26,534
+44% +$212K ﹤0.01% 4293
2023
Q3 		$583K Buy
59,968
+23,851
+66% +$140K ﹤0.01% 4383
2023
Q2 		$162K Buy
36,117
+3,646
+11% +$16.5K ﹤0.01% 4787
2023
Q1 		$151K Sell
32,471
-2,076
-6% -$7.95K ﹤0.01% 4863
2022
Q4 		$51.5K Buy
34,547
+9,101
+36% +$20.2K ﹤0.01% 5221
2022
Q3 		$95K Buy
25,446
+3,360
+15% +$16.2K ﹤0.01% 5190
2022
Q2 		$109K Sell
22,086
-313,116
-93% -$2.07M ﹤0.01% 5219
2022
Q1 		$2.75M Sell
335,202
-4,885
-1% -$42.1K ﹤0.01% 4256
2021
Q4 		$3.43M Buy
340,087
+6,113
+2% +$79.4K ﹤0.01% 4167
2021
Q3 		$5.29M Sell
333,974
-521
-0.2% -$10.9K ﹤0.01% 3936
2021
Q2 		$7.96M Buy
+334,495
New +$7.76M ﹤0.01% 3723

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's NPCE Position: Q2 2026 in Review

BlackRock increased its Neuropace (NPCE) stake by 5.6% in Q2 2026, buying an estimated $2.11M and bringing the position to 2,477,603 shares worth $39.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2826.

BlackRock first reported a position in NPCE in Q2 2021 and has held it in 21 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • BlackRock held 2,477,603 shares of Neuropace worth $39.4M as of Q2 2026.
  • BlackRock bought 131,270 Neuropace shares in Q2 2026, an estimated $2.11M.
  • Neuropace made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2826 holding.
  • BlackRock first reported a position in Neuropace in Q2 2021 and has held it in 21 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.